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Identity 
Other names: ADABP, ADCP2, CD26, DPPIV, 
TP103 




In 1979, a large molecular weight complex composed 
of adenosine deaminase (ADA) were reported to be 
found as an adenosine deaminase-binding protein 
(ADBP), also known as adenosine deaminase 
complexing protein-2 (ADCP2). In 1993, this 
adenosine deaminase-binding protein is determined to 
be identical to CD26, a T-cell activation molecule and a 
110-kD glycoprotein that is present also on epithelial 
cells of various tissues including the liver, kidney, and 
intestine. The CD26 cDNA contains a 3465 bp open 
reading frame that encodes a 766 amino acid protein. 
The CD26 amino acid sequence has 85% amino acid 
identity with the  
mouse and rat CD26 genes and 37% amino acid 
identity with D. melanogaster.  
Two CD26 transcripts (4,2 and 2,8 kb) were found, 
both of which were expressed at high levels in the 
placenta and kidney and at moderate levels in the lung
and liver. However, only the 4,2 kb mRNA was 
expressed at low levels in skeletal muscle, heart, brain, 
and pancreas. 
Transcription 
The 5'-flanking region does not contain a TATA box or 
CAAT box, commonly found in housekeeping genes. 
CD26 does contain a 300 base-pair G-C rich region 
with potential binding sites for NF-κB, AP2, or Sp1. 
CD26 expression is activated by interferons (IFNs) and
retinoic acid in chronic lymphocytic leukemia (CLL) 
via Stat1α and the GAS response element 
(TTCnnnGAA located at bp -35 to -27) in the CD26 
promoter. A hepatocyte nuclear factor 1 binding site at 
position -150 to -131 of the CD26 gene regulates CD26 
expression in human intestinal (Caco-2) and hepatic 
epithelial (HepG2) cell lines. 
 
 
Location of DPP4 gene on chromosome 2q24.3. DPP4 spans 82,301 kbp of chromosome 2 from 162848751 to 162931052. The gene 
contains 26 exons (indicated in orange squares), ranging from 45 to 1,4 kb in length on the reverse strand. The Ser recognition site (G-
W-S-Y-G) is split between exons 21 and 22. 
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The schematic diagrams of the amino acids of DPP4. The cDNA of DPP4 is composed of 2301 base pairs, translated to 766 amino 
acid protein. CD26/DPP4 is a ubiquitous, membrane-bound enzyme that has roles in nutrition, metabolism, the immune and endocrine 
systems, bone marrow mobilization, cancer growth and cell adhesion. DDPIV catalyzes the hydrolysis of N-terminal dipeptides from 
polypeptides with proline or alanine in the penultimate position. Note: residues 1-6: cytoplasmic domain (MKTPWK); residues 7-29: 
transmembrane domain (VLLGLLGAAALVTI ITVPVVLLN); residues 30-48: flexible stalk (KGTDDATADSRKTYTLTDY); residues 201-
211 and Ser603: caveolin-1 binding site (WVYEEEVFSAY); residues 340-343: ADA binding site (LVAR); residues 469-479: fibronectin 
binding site (QLRCSGPGLPL); red *: essential for DPPIV activity (Glu205,Glu206 and Tyr547); green underlined GWSYG: serine 
recognition site; black *: Ser630, Asp708, His740 active site triad; red boxes: odd numbered exons; green boxes: glycosylation sites; 
yellow box (His750): required for homodimer formation; white square at residue 492: non-synonymous cSNP (Arg492Lys); white triangle 




CD26 is a multifunctional type II transmembrane serine 
peptidase that has an extracellular domain with DPPIV 
enzymatic activity and a short cytoplasmic domain. It 
interacts with extracellular molecules and is also 
involved in intracellular signal transduction cascades. 
CD26 is important in immunology, autoimmunity, 
HIV, diabetes, and cancer. Interacting directly with 
various other cell surface and intracellular molecus, 
CD26 can regulate receptor specificity via its DPPIV  
 
activity and the function of various chemokines and 
cytokines. CD26 is expressed at low density on resting 
T cells, but is upregulated with T cell activation. 
Therefore, CD26 may have an important functional role
in T-cells and overall immune function. CD26 
associates with other important immunologic cell 
surface receptors such as CD45, CD9 and CXCR4.  
The multifunctional activities of CD26 are dependent 
on cell type and intracellular or extracellular conditions 
that influence its role as a proteolytic enzyme, cell
surface receptor, costimulatory interacting protein and 
signal transduction mediator; as well as its role in 
adhesion and apoptosis. 
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Schematic representation of CD26/DPPIV. Human CD26 is composed of 766 amino acids, including a short cytoplasmic domain of 6 
amino acids, a transmembrane region of 24 amino acids, and an extracellular domain with dipeptidyl peptidase activity which selectively 
removes the N-terminal dipeptide from peptides with proline or alanine at the penultimate position. Single amino acid point mutation in 
the β-propeller motif identified Glu205 and Glu206 as essential for DPPIV enzyme activity, and the central tunnel and α/β-hydrolase 
domains both participate in DPPIV inhibitor binding. Single amino acid point mutation at His750 residue is responsible for dimerization. 
 
Description 
Originally characterized as a T cell differentiation 
antigen, CD26 is preferentially expressed on a specific 
population of T lymphocytes, the subset of 
CD4+CD45RO+ memory T cells, and is upregulated 
following T cell activation. Besides being a marker of 
T cell activation, CD26 is also associated with T cell 
signal transduction processes as a costimulatory 
molecule. Recent work also suggests that CD26 has a 
significant role in tumor biology, being both a marker 
of disease behavior clinically as well as playing an 
important role in tumor pathogenesis and development. 
For instance, the association of CD26/DPPIV with such 
key molecules as topoisomerase IIα, p38 MAPK, and 
integrin β1, has important clinical implications, 
including its potential ability to regulate tumor 
sensitivity to selected chemotherapies and to influe ce 
tumor migration/metastases and tumorigenesis. DPPIV 
inhibitors enhance the effects of incretin hormones 
(glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP)), increasing 
glucose-mediated insulin secretion and suppressing 
glucagon secretion. Therefore, DPPIV inhibitors, which 
act by inhibiting DPPIV, the enzyme that inactivates 
GLP-1 and GIP have been available as a new class of 
antidiabetes drugs. 
Expression 
CD26 is expressed in many tissues. Two CD26 
transcripts (4,2 and 2,8 kb) are reported to be found, 
both of which were expressed at high levels in the 
placenta and kidney and at moderate levels in the lung
and liver. The 4,2 kb transcript was expressed at low 
levels in skeletal muscle, heart, brain, and pancreas. 
Other organs expressing CD26 include: brain, 
endothelium, heart, intestine (colon adenocarcinoma, 
fetal colon expression disappears at birth), kidney, 
liver, lung, skeletal muscle, pancreas, and placenta. I  
the hematopoietic system CD26 is found on CD4+ T 
memory cells, CD8+ effector/memory T cells. 
It has been reported that 0-5% of freshly isolated 
CD20+ B cells do express the CD26 antigen. Following 
stimulation with PMA (phorbol 12-Myristate 13-
acetate) or Streptococcus aureus protein, the fraction of 
CD26-positive cells increased to 51%. 
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3-D structure of CD26/DPPIV. CD26/DPPIV forms a homodimer in the cell surface membrane. The residues 7-28 constitute the 
membrane spanning region. Each subunit consists of two domains, that is, an α/β-hydrolase domain and a β-propeller domain. The N-
terminal β-propeller domain of CD26/DPPIV (residues 55-497) consists of 8 blades. β-strand 2 of blade 4 of the propeller extends into a 
small domain (residues 234-260) that includes an antiparallel two-stranded β-sheet. The function of this arm is to stabilize the dimeric 
structure. The catalytic site (Ser630-Asp708-His740) is located in a large cavity (also called a central tunnel), formed between the α/β-
hydrolase domain and 8-bladed β-propeller domain, which contains the consensus sequence (DW(V/L)YEEE), that is common to S9b 
proteases. The central tunnel and α/β-hydrolase domains both participate in inhibitor binding. This figure is reproduced from Ralf Thoma 
et al., Structural Basis of Proline-Specific Exopeptidase Activity as Observed in Human Dipeptidyl Peptidase-IV, Structure 2003;8:947-
959, with permission by Elsevier Limited. 
 
 
Meanwhile, CD26 is not expressed or is found only at 
low levels on monocytes of healthy adult. Flow 
cytometric analysis of dendritic antigen-presenting 
cells (DC) generated from peripheral blood of normal 
donors in the presence of granulocyte/macrophage 
colony-stimulating factor and revealed intermediate 
levels of CD26 expression during a 2-week culture 
period. Only a small fraction of peripheral NK cells 
was found to express CD26. 
Localisation 
CD26 physically binds with ADA, an enzyme that 
plays a key role in the development and function of 
lymphoid tissues. ADA is essential for purine 
metabolism, with the loss of ADA leading to a clinical 
syndrome characterized by severe immunodeficiency. 
When the ADA inhibitor pentostatin was used in the 
treatment of recurrent T cell lymphomas, a significant 
reduction in circulating CD26+ T cells was observed in 
treated patients. This finding is consistent with the fact 
that there is a physical association between CD26 and 
ADA on the surface of T lymphocytes. CD26 also 
interacts with CD45RO, a tyrosine phosphatase with a 
critical role in T cell signal transduction, at lipid rafts in 
peripheral blood T lymphocytes to modify cellular 
signaling events. A lipid raft is a cholesterol-rich 
microdomain in cell membrane, which plays an 
important role in signal transduction in T-cell 
regulation. CD26 interaction with lipid rafts in 
peripheral blood T-cells influences key cellular 
signaling events. Non-activated peripheral blood T-
cells treated with the anti-CD26 mAb 1F7 increased 
CD26 recruitment to lipid rafts, resulting in increased 
tyrosine phosphorylation of c-Cbl, Zap70, Erk1/Erk2, 
p56lck, and TCR-ζ. Interestingly, CD26 is associated 
with CD45 RA outside of lipid rafts in cord blood T 
cells, and the strong physical linkage of CD26 and 
CD45 RA may be responsible for the attenuation of 
cord blood T-cell activation signaling through CD26. In 
addition to cell surface expression, nuclear localization 
of CD26 has been reported in malignant mesothelioma 
and malignant T cell lines, and in human thyroid 
carcinomas, although little is known on the functional 
relevance of nuclear CD26. In addition to membrane 
bound CD26, soluble form of CD26 (sCD26) is also 
detected in the sera, urine, thoracic fluid and seminal 
fluid. sCD26 in the sera appears to be functioned as 
immune enhancing protein in antigen-presenting cell
(APC). 
Function 
CD26 is a co-stimulatory molecule for T-cell signal 
transduction. While CD26 expression is enhanced 
following activation of resting T cells, CD4+CD26high T 
cells respond maximally to recall antigens such as 
tetanus toxoid. Moreover, we have previously reproted 
that effector CD26-mediated costimulatory activity is 
exerted via its DPPIV enzymatic activity.  










In addition, CD4+ T cells with in vitro transendothelial 
migratory capacity appear to express high CD26, 
indicating a role for CD26 in the migration of T cells, 
and patients with autoimmune diseases such as multiple 
sclerosis, Grave's disease, and rheumatoid arthritis 
(RA) have been found to have increased numbers of 
CD4+CD26+ T cells in inflamed tissues as well as in 
their peripheral blood, with enhancement of CD26 
expression in these autoimmune diseases correlating 
with disease severity. Moreover, CD26highCD8+ T cells 
in humans belong to early effector memory T cells, and
CD26highCD8+ T cells increase expression of granzyme 
B, TNF-α (tumor necrosis factor-α), IFN-γ and Fas 
ligand, and exert cytotoxic effect with CD26-mediated 
costimulation. CD26 binds to caveolin-1 on APC, and 
residues 201 to 211 of CD26 along with the serine 
catalytic site at residue 630, which constitute a pocket 
structure of CD26/DPPIV, contribute to binding to the 
caveolin-1 scaffolding domain. This region in CD26 
contains a caveolin-binding domain 
(ΦΧΦΧΧΧΧΦΧΧΦ; Φ and Χ depict aromatic residue 
and any amino acid, respectively), specifically 
WVYEEEVFSAY in CD26. These observations 
strongly support the notion that DPPIV enzyme activity 
is necessary to exert T-cell costimulatory activation via 
CD26 as demonstrated in our previous report using 
CD26 specific mAbs. The cytoplasmic tail of CD26 is 
responsible for T-cell costimulation induced by anti-
CD3 plus caveolin-1. It has been identified that 
CARMA1 binds to the cytoplasmic tail of dimeric 
CD26, and that a PDZ domain in CARMA1 is 
necessary for binding to CD26. Following its 
phosphorylation, CARMA1 functions as a signaling 
intermediate downstream of PKCθ and upstream of 
IKK in the TCR signaling transduction pathway 
leading to NF-κB activation. Dimeric CD26, but not 
monomeric CD26, binds to CARMA1. The enzymatic 
pocket structure of the DPPIV catalytic site is 
necessary for binding of CD26 to caveolin-1, leading to 
the upregulation of CD86 expression on APC. 
Therefore, dimerization of CD26 is not only necessary 
for binding to caveolin-1, but also serves as a 
scaffolding structure for the cytoplasmic signaling 
molecule CARMA1. Overall, CD26 ligation by 
caveolin-1 on APC recruits CD26-interacting 
CARMA1 to lipid rafts, resulting in the formation of a 
CARMA1-Bcl10-MALT1-IKK complex, and this 
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membrane-associated Bcl10 complex then activates 
IKK through ubiquitination of NEMO. 
DPPIV inactivates incretin hormone (glucagon-like 
peptide-1 (GLP-1) and glucose-dependent 
insulinotropic polypeptide (GIP)). Therfore, DPPIV 
inhibitors enhance the effects of GLP-1 and GIP, 
increasing glucose-mediated insulin secretion and 
suppressing glucagon secretion.  
In this regard, DPPIV inhibitors are now avalilable 
worldwide for use of an antidiabetic drug. Moreover, 
DPPIV cleaves many cytokines and chemokines, which 
are summerized in Table 1.  
Morimoto et al. showed that proinflammatory 
cytokines such as TNF-α or IL-1β reduce expression of 
CD26 in microvascular endothelial cells, and that 
genetical or pharmacological inhibition of 
CD26/DPPIV enhances endothelial growth both in 
vitro and in vivo.  
These data strongly suggest that this effect of DPP-4 
inhibition on endothelial growth may be of potential 
use in treating diabetic vascular complications, as well 
as diabetes itself. 
Homology 
CD26/DPPIV molecure is involved in DPPIV activity 
and/or structure homologues (DASH), comprising 
seprase, fibroblast activation protein α (FAP-α), DPP6, 
DPP8, DPP9, attractin, N-acetylated-α-linked-acidic 
dipeptidase I, N-acetylated- α linked-acidic dipeptidase 
II and N-acetylated-α-linked-acidic dipeptidase L, 
quiescent cell proline dipeptidase, thymus-specific 
serine protease and DPPIV-β. 
Mutations 
Note 
Several polymorphisms in the CD26/DPPIV gene 
coding region have been deposited in the National 
Center for Biotechnology Information single nucleotide 
polymorphism (SNP) database (NCBI). The functional 
significance of coding region SNPs (cSNPs), non-
cSNPs, or other polymorphisms has not been 
determined.  
Synonymous (non-amino acid changing) 
polymorphisms include the following (N.D. indicates 
not determined):  
Leu8 (T->C, exon 2, frequency: N.D.), Ile405 (C->T, 
exon 14, frequency: heterozygosity 0.056), Gly645 (C-
>T, exon 22, frequency: N.D.), Tyr661 (C->T, exon 22,
frequency: N.D.).  
The non-synonymous cSNP Arg492Lys (G->A, exon 
18, frequency: N.D.) functional significance has not yet 
been determined.  
CD26 experimental mutations include:  
- Glu205 and Glu206 mutants (DPPIV negative 
activity)  
- Leu294, Leu340, Val341, Ala342, Arg343, Thr440, 
and Lys441 mutants (ADA binding)  
- Ser630Ala (DPPIV negative activity)  
- Gly633Arg (retention and degradation of mutant 
protein in the endoplasmic reticulum)  
- His750Glu (stable dimerization). 
Implicated in 
Adult T-cell leukemia/lymphoma 
Note 
A study of the human T-lymphotropic virus 1 (HTLV-
1) related cancer adult T-cell leukemia/lymphoma 
(ATLL) showed a reduction of surface CD26 
expression in the peripheral blood mononuclear cells.  
Additionally, CD26 mRNA was undetectable in 7 of 8 
ATLL patients. Quantification of HTLV-1 viral DNA 
by PCR in cells from subjects with CD26-, CD26+, and 
17 HTLV-1 carriers showed that the CD26- cells had a 
higher HTLV-1 copy number than CD26+ cells.  
This suggests that HTLV-1 has tropism for CD26- cells 
in vivo. In a study of 49 patients with ATLL, 10 
subjects that were carriers of HTLV-1, and 4 HTLV-1 
infected cell lines, ATLL HTLV-I-infected cell had 
reduced or absent the CD26/DPPIV expression. CD26 
expression decreased with the advancement of ATLL 
stage. This appeared to be due to progressive aberrant 
methylation of CpG islands in the CD26 promoter 
proportional to increasing ATLL stage. This was 
confirmed with rescue experiments with the 
demethylating agent, 5-azacytidine. 
Non-Hodgkin's lymphoma 
Note 
In Non-Hodgkin's lymphoma (NHL), CD26 expression 
is found mainly in aggressive subtypes, such as T-
lymphoblastic lymphoma (LBL)/T-acute lymphoblastic 
leukemia (ALL) and T-cell CD30+ anaplastic large cell 
lymphoma (ALCL). CD26 and CD40L (CD154) 
expression was mutually exclusive, with CD40L 
expressed on cells from more indolent diseases. CD26 
expression in T-cell LBL/ALL was associated with a 
worse survival. The majority of patients with T-ALL 
express CD26 on the leukemic cell surface. There 
appears to be high CD26/DPPIV expression on T-
lymphoblasts but only moderate DPPIV activity. 
Aldinucci et al. showed that CD26 is a marker of poor 
prognosis in T-cell cancer and is a predictive marker of 
poor response to 2'-deoxycoformycin, pentostatin. This 
effect was seen in vitro in CD26/ADA positive 
leukemia/lymphoma T-cell lines, primary CD26+ T-cell 
cancers, and normal T-cells (CD26+). Loss of CD26 
appears to be characteristic of cutaneous T-cell 
lymphoma (CTCL) and has been suggested as a useful 
diagnostic marker. 
Sezary syndrome/mycosis fungoides 
Note 
CD26 expression is absent or weak in other T-cell 
lymphomas such as mycosis fungoides (MF) and 
Sezary syndrome (SS).  
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SS is a form of CTCL involving the blood and skin. 
Loss of CD26 appears to be characteristic of CTCL and 
has been suggested as a useful diagnostic marker. 
Chemokines and their receptors are involved in 
recruitment and homing of cancer cells to tissues of 
several tumors including non-Hodgkin's T-cell 
lymphomas. SS cells express CXCR4 and the skin 
generates its ligand, SDF-1, which may represent a 
target for the main destination of SS cells metastasizing 
to the skin. SDF-1 (CXCL12) is normally cleaved and 
inactivated by DPPIV mediated activity. An abnormal 
CD26-negative/dim T-cell population was found in a 
study of 66 of 69 samples from 28 SS/MF patients. 
These CD26negative/dim T-cells were CD26 negative in 23 
patients and CD26-weakly positive in 5 patients. 
Sokolowska-Wojdylo and colleagues found that 
absence of CD26 on CLA (cutaneous lymphocyte-
associated antigen)+ CD4+ T-cells was 100% sensitive 
for SS in 7 patients. Also, the number of CD26-
negative T-cells correlated with treatments in 2 patients 
for over 1 year in a longitudinal study. SS patients have 
decreased plasma DPPIV activity. Soluble CD26 
reduces the SDF-1 mediated SS cell migratory 
response. Inhibition of DPPIV activity in the CD26+ 
CTCL cell line Hut78 increases SDF-1-induced 
migration of SS cells. The SDF-1-CXCR4 interactions 
may mediate SS cell affinity for skin as a metastatic 
site via the regulatory activity of CD26. 
T-large granular lymphocyte 
lymphoproliferative disorder 
Note 
CD26 expression is associated with a more aggressive 
clinical course in T-cell large granular lymphocyte 
leukemia (T-LGLL). T-LGLL patients with low 
expression of CD26 on T-LGLL cells had a more 
indolent course, while patients with high expression 
developed recurrent infections due to neutropenia. 
LGLL patients often have autoimmune diseases. CD26 
expression on T-LGLL is associated with inhibition f 
myeloid progenitors, possibly explaining the 
neutropenia seen in these patients with higher levels of 
CD26 expression. CD26 on T-LGLL cells is unable to 
transmit antibody-mediated activation signals, unlike 
CD26 on normal T-cells, so CD26-related signaling 
may be aberrant in T-LGLL. In a recent report of a 
single institution long-term follow-up of 21 T-LGLL 
patients, 0 of 21 had CD26 expression. 
Breast cancer 
Note 
Cheng et al. found that CD26 expressed on rat lung 
capillary endothelium mediated lung metastases of 
breast cancer cells by association with fibronectin. 
They studied the Fischer 344/CRJ rats, which have a 
CD26 Gly633Arg substitution, that leads to retentio 
and degradation of the mutant protein in the 
endoplasmic reticulum, as a "protein knock-out" model  
to characterize the previously established role of CD26 
in metastasis. They found that lung metastases from the 
highly metastatic MTF7 rat breast cancer cell line were 
reduced by only 33% relative to normal Fischer 344 
rats. Detailed immunohistochemical experiments 
revealed low levels of mutant enzymatically inactive 
CD26 on lung endothelial cells. When the mutant 
CD26 was purified, it had identical adhesion qualities 
for breast cancer cells as wild type DPPIV. The 
CD26/fibronectin-mediated adhesion and metastasis are 
effectively competed by soluble CD26, anti-CD26 
mAb 6A3, and anti-fibronectin antiserum. Furthermore, 
peptides containing the fibronectin CD26-binding 
domain blocked the CD26-fibronectin interaction and 
significantly decreased pulmonary metastasis of breast 
cancer and melanoma cell lines. The utilization of 
fibronectin by cancer cells and fibronectin self-
association in the blood suggests that CD26/fibronecti  
binding may be a mechanism for lung metastasis. 
CD26 is associated with increased topoisomerase IIa 
levels and tumor sensitivity to the topoisomerase II 
inhibitors, such as doxorubicin and etoposide. Recent 
studies suggest that topoisomerase IIα level is a 
prognostic factor in breast cancer that is independent of 
stage, Her-2/neu status, and histological grading. 
Furthermore, anthracycline treatment did not reverse 
the negative prognostic effect of topoisomerase IIα 
expression. Others have found, in retrospective studies 
that topoisomerase IIα overexpression confers a higher 
probability of response to doxorubicin. Topoisomeras  
IIα is currently being evaluated prospectively as a 
breast cancer predictive marker. The role of CD26 in 
breast cancer and the interaction of CD26 with 
topoisomerase IIα is an area for future research. 
Colon cancer 
Note 
CD26 is found on the cell surface and its level 
correlates with disease status and tumor biology for 
certain cancers. In colorectal cancer, soluble CD26 
(sCD26) in the sera was not related to colon cancer 
grade, stage, or location. The DPPIV inhibitor PT-100 
(Val-boro-Pro) improved the activity of trastuzumab in 
human Her2+ colon cancer in xenograft models. 
However, the anti-cancer activity of PT-100 was not
changed in CD26-/- mice, suggesting non-CD26 
mediated activity. Cordero et al. found that the sCD26 
concentration is diminished in serum of colorectal 
cancer patients compared to healthy donors, suggestin  
the potential utility of a sCD26 immunochemical 
detection test for early diagnosis. Pang et al. have 
identified a subpopulation of CD26+ cells uniformly 
present in both the primary and metastatic tumors in 
colorectal cancer patients with liver metastasis. 
Furthermore, in patients without distant metastasis t 
the time of presentation, the presence of CD26+ cells in 
their primary tumors predicted distant metastasis on 
follow-up. 
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Lung cancer 
Note 
CD26 is expressed in lung adenocarcinoma but not 
other subtypes of lung cancer. CD26 expression and 
DPPIV activity are present in normal bronchial and 
alveolar epithelium, but non-adenocarcinoma lung 
cancers lose CD26 expression. CD26 downregulation 
may contribute to the loss of growth control in non-
small cell lung carcinoma (NSCLC) cells.  
NSCLC cells transfected with CD26 develop 
morphologic changes, altered contact inhibition, and 
reduced ability for anchorage-independent growth. An 
increased percentage of cells in G0-G1 was noted in 
CD26 expressing cells, indicating CD26 may promote 
cell cycle arrest. Amatya and colleagues assessed the 
diagnostic utility of caveolin-1 (Cav-1), a ligand for 
CD26, which is expressed in endothelial cells, alveolar 
type I pneumocytes and mesothelial cells, as a novel 
positive marker of mesothelioma. 
Immunohistochemical study of 80 cases of epithelioid 
mesothelioma and 80 cases of lung adenocarcinoma 
was performed for the analysis of the expression of 
Cav-1 and other markers. Cav-1 expression with a 
membranous and/or cytoplasmic pattern was found in 
all of the epithelioid mesothelioma. Of these, 42 cases 
(52,5%) showed Cav-1 expression in >50% of tumour 
cells, 34 cases (42,5%) in 6-50% of tumour cells, and
four cases (5,0%) in <5% of tumour cells. In contrast, 
only six cases (7,5%) of lung adenocarcinoma showed 
focal Cav-1 expression in the cytoplasm of the tumor 
cells. They concluded that Cav-1 is a novel 
immunohistochemical marker for the differentiation f 
epithelioid mesothelioma from lung adenocarcinoma. 
Hepatocellular carcinoma 
Note 
In normal liver as well as cirrhotic and steatotic liver, 
CD26 is expressed in the bile canalicular domains of 
hepatocellular membranes. In hepatocellular carcinoma 
(HCC), CD26/DPPIV activity was lost (2/25 cases) or 
had altered distribution (23/25 cases). Gaetaniello and 
colleagues found Tyr phosphorylation of several 
proteins after antibody binding to CD26 in HCC cell 
lines. This effect was inhibited by CD45 Tyr 
phosphatase. They found that a protein or proteins w th 
kinase activity were associated with CD26. CD26 
protects against apoptosis in Jurkat T-cells, while in the 
human hepatoma PLC/PRF/5 cells CD26 antibody 
binding is pro-apoptotic. CD26 expression is also pr -
apoptotic in HepG2 cells. 
Glioma 
Note 
Low CD26/DPPIV activity is found in poorly 
differentiated gliomas and high activity is found in
differentiated gliomas. Differentiated gliomas have 
higher levels of membrane-associated isoforms of 
CD26/DPPIV. Sedo and colleagues studied "DPPIV 
activity and or structure homologs" (DASH) in 5 
glioma cell lines of varying grade. They concluded that 
there was "no simple correlation with the degree of 
malignancy of the original donor tumor or morphologic 
phenotype...". They did note that changes in DASH 
composition as detected by non-denaturing 
polyacrylamide gel electrophoresis may reflect changes 




CD26/DPPIV biochemical activity was twice as high in 
prostate cancer compared to benign prostate 
hyperplasia (BPH) tissues. CD26/DPPIV activity was 
also increased in BPH adjacent to cancerous prostate 
tissue. DPPIV activity was present in epithelial but not 
stromal BPH and cancer tissues. This suggests that 
paracrine factors produced by prostate cancer cells may 
modulate the local microenvironment to increase 
cancer growth. Johnson et al. found that lung 
endothelial cells with metastatic prostate cancer cells 
were enriched for CD26 compared to non-metastatic 
prostate cancer cells. However, Wesley et al. suggested 
that CD26 inhibits the "malignant phenotype" of 
prostate cancer cells by inhibiting the FGF signaling 
pathway. Wilson et al. examined DPPIV activities in 
different prostatic tissue zones and in prostatic 
expressed secretions in relation to the presence of 
cancer. They found that expressed prostate secretions in 
patients with cancer were higher than in men withou 
cancer. DPPIV activities in the transitional and 
especially the peripheral zone biopsies were higher in 
cancer patients. They concluded that secreted DPPIV 
originates in the transitional and peripheral zones. 
Measuring DPPIV levels in prostate secretion or in 
post-digital rectal prostate examination urine may be a 
useful for tumor marker for prostate cancer. Gonzalez-
Gronow et al. found that in addition to its ability o 
inhibit tumor vascularization, angiostatin 2ε may also 
directly block prostate cancer metastasis by binding to 
CD26 on the surface of the 1-LN prostate cancer cell 
line. CD26/DPPIV association with plasminogen may 
lead to signal transduction that regulates expression of 
MMP-9 in prostate cancer cells. CD26 inhibitors may 
inhibit prostate cancer by blocking a CD26/DPPIV 
mediated signal transduction pathway that regulates 
MMP-9 expression by prostate cancer cells. 
Renal cancer 
Note 
CD26 expression has previously been noted in renal 
cell carcinoma, with unclear significance. CD26 has a 
high level of surface expression on the renal cell 
carcinoma cell lines Caki-1, Caki-2, VRMRC-RCW, 
and ACHN. Inamoto and colleagues showed that anti-
CD26 monoclonal antibody inhibition of the Caki-2 
cell line was associated with G1/S cell cycle arrest, 
enhanced kip1 ID: 116> expression, down regulation of 
cyclin-dependent kinase 2 (CDK2) and 
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dephosphorylation of retinoblastoma substrate (Rb). 
They also found that anti-CD26 monoclonal antibody 
therapy attenuated Akt activity and internalized cell 
surface CD26 leading to decreased CD26 binding to 
collagen and fibronectin. More importantly, they 
showed that anti-CD26 monoclonal antibodies 
inhibited human renal cell carcinoma cell growth in a 
mouse xenograft model, with prolongation of survival. 
These results suggest that CD26 is a good target for 
renal cell carcinoma. 
Thyroid cancer 
Note 
Benign thyroid tissue is usually negative for CD26 
expression, but CD26 expression has been observed in 
thyroid cancer. This difference has been exploited as a 
diagnostic marker for the differential diagnosis of
benign thyroid disease versus thyroid cancer. Kholová 
et al. suggest that CD26 positivity is limited to well-
differentiated thyroid carcinomas including papillary 
carcinoma and is of limited value for diagnosing 
follicular and oncocytic thyroid malignancies. 
Melanoma 
Note 
CD26 is highly expressed in normal melanocytes, but 
not in melanoma cells, suggesting CD26 expression is 
lost in malignant transformation. Loss of CD26 was 
also associated with development of specific 
chromosome abnormalities. When CD26/DPPIV is 
expressed in melanoma cells using a tetracycline-
inducible expression system, melanoma growth was 
suppressed in the clones of cell line expressing higher 
levels of CD26. CD26 expression also decreased the 
melanoma growth in soft agar - indicating a CD26 
association with anchorage-independent growth. Also, 
CD26 can induce MMP-9 expression in cancer cells, 
which may facilitate metastasis. Pethiyagoda et al. 
confirmed that CD26/DPPIV inhibits invasion of 
malignant melanoma cell lines by transfecting CD26 
into melanoma cell lines. Invasion in Matrigel was 
decreased by 75%. This was also true for CD26 mutant 
transfectants that either lacked the extracellular 
protease activity (Ser630Ala) or the six amino acid 
cytoplasmic domain - demonstrating that neither 
DPPIV activity or the six amino acid C-terminal 
domain were necessary to inhibit invasiveness. 
Expression of either wild-type CD26 (DPPIV positive) 
or mutant CD26 (DPPIV negative) rescued expression 
of the cell surface Ser protease FAP-α. FAP-α can form 
a heterodimer with CD26 and may play a role in 
regulating melanocyte/melanoma growth. CD26 can 
inactivate circulating growth hormone-releasing factor 
(GHRF), so decreased CD26 may result in cancer 
growth by increased GHRF. A recent study found no 





Expression of CD26 varies in ovarian cancer cell lines. 
CD26 is negatively correlated with ovarian cancer 
invasive potential. Specifically, overexpression of
CD26 in ovarian cancer leads to increased E-cadherin 
and tissue inhibitors of MMPs, resulting in decreased 
invasive potential. CD26 transfection in ovarian cacer 
cell lines decreased intraperitoneal dissemination and
prolonged survival in vivo in mice. 
Malignant mesothelioma 
Note 
Malignant pleural mesothelioma (MPM) is an 
aggressive cancer arising from the mesothelial cells 
lining the pleura. Morimoto et al. showed that CD26 is 
preferentially expressed on malignant mesothelioma 
cells but not on normal mesothelial cells, and suggested 
that membranous expression of CD26 indicates an 
importance in treatment of patients with MPM. More 
importantly, humanized anti-CD26 antibody inhibited 
growth of malignant mesothelioma cells and induced 
long term survival of tumor-transplanted SCID mice. In 
addtion, it has been shown that cells from certain 
CD26-positive mesothelioma cell lines appeared to 
include the cancer stem cell characteristics for 
malignant mesothelioma in addition to CD24 and CD9-
positive cells. Furthermore, Morimoto et al. showed 
that the CD26 molecule is expressed on the cell 
membrane of the epithelial and biphasic, but not the 
sarcomatoid, type of mesothelioma. Importantly, 
treatment outcome prediction study showed that CD26 
membrane expression on MPM was closely correlated 
with disease responsiveness to chemotherapy. 
Meanwhile, in vitro studies showed that mesothelioma 
cells expressing high level of CD26 displayed high 
proliferative activity, and microarray analysis of CD26 
knockdown and CD26-transfected mesothelioma cells 
showed that CD26 expression was closely linked to 
expression of genes contributing to cell proliferation, 
cell cycle regulation, drug-induced apoptotic action, 
and chemotherapy resistance. These data therefore 
strongly suggest that the CD26 molecule is a good 
therapeutic target for MPM and a clinically significant 
biomarker for the prediction of response to 
chemotherapy for MPM. 
Gastric gastrointestinal stromal tumors 
Note 
In an immunohistochemical analysis of 152 patients 
with gastric gastrointestinal stromal tumors (GIST), 
CD26 expression was found to be associated with a 
poorer overall survival. 
Rheumatoid arthritis 
Note 
Rheumatoid arthritis (RA) is a chronic, inflammatory  
autoimmune disease and is characterized by  
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progressive invasion of synovial fibroblasts into the 
articular cartilage and erosion of the undelying bone, 
followed by joint destruction. In antigen-induced 
arthritis mouse model, DPPIV-/- mice showed more 
severe arthritis, and enzymatic activity levels of DPPIV 
in the plasma were significantly decreased in RA 
patients. Morever, other investigators reported that 
inhibition of DPPIV and FAP increases cartilage 
invasion by RA synovial fibroblasts. However, 
CD26/DPPIV regulates biologic processes that are 
unrelated to its peptidase activity, e.g., cellular 
adhesion, cell differentiation, and activation via 
downstream signaling cascade. CD26+ T cells induce 
the inflammation and tissue destruction characteristic 
of RA by migrating to and being active in the 
rheumatoid synovium. Cordero et al. studied IL-12, IL-
15, soluble CD26, and ADA serum levels from 35 
patients with active and inactive RA as well as those f 
controls. Patients' sera had higher IL-12 and IL-15 
levels, and the level of soluble CD26 was inversely 
correlated with the number of swollen joints. These 
findings suggest that these cytokines and CD26 are 
associated with the inflammation and immune activity 
in RA. Mavropoulos et al. found that anti-TNF-α 
therapy increases DPPIV activity and decreases 
autoantibodies to the chaperone protein Bip (GRP78) 
and phosphoglucose isomerase in 15 patients with RA. 
DPPIV inhibitors inhibit a rat model of rheumatoid 
arthritis in a dose-dependent manner. Ohnuma et al. 
described CD26+ T cells infiltrating the rheumatoid 
synovium using immunohistochemical studies. They 
found high expression of caveolin-1 in the rheumatoid 
synovium vasculature and synoviocytes. These data 
suggest that the CD26-caveolin-1 upregulation of 
CD86 on activated monocytes leads to antigen-specific 
T-cell activation in rheumatoid arthritis. DPPIV 
inhibitors may be useful for suppressing the immune 
system in rheumatoid arthritis and other autoimmune 
diseases. 
Inflammatory bowel diseases 
Note 
Crohn's disease and ulcerative colitis are categorized as 
inflammatory bowel disease (IBD), being characterized 
by chronic remittent or progressive inflammatory 
conditions that may affect the entire gastrointestinal 
tract and the colonic mucosa, respectively, and are 
associated with an increased risk for colon cancer. S a 
from IBD patients contain lower levels of circulating 
DPPIV activity, while membrane expression of 
CD26/DPPIV on T cells isolated from IBD patients is 
higher than healthy controls. These clinical 
observations indicate that CD26/DPPIV might play a 
significant role in perpetuating the inflammatory 
response associated with IBD. 
Systemic lupus erythematosus 
Note 
Serum levels of soluble CD26 and its specific DPPIV  
activity were significantly decreased in patients with 
systemic lupus erythematosus (SLE), and were 
inversely correlated with SLE disease activity index 
score, but not with clinical variables or clinical subsets 
of SLE.  
More recently, Lam et al. reported that CD26 
expression on invariant natural killer cells of SLE 
patients is decreased significantly than that of healt y 
controls. 
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